{
    "clinical_study": {
        "@rank": "25107", 
        "arm_group": {
            "arm_group_label": "IQP-MM-101", 
            "arm_group_type": "Experimental", 
            "description": "Dissolve the effervescent tablets in half a glass of water,to be taken orally\n1 tablet, 3 times a day"
        }, 
        "brief_summary": {
            "textblock": "Diosmectite in IQP-MM-101 has been used for diarrhoea control. Backed by data from several\n      studies demonstrating their efficacy, the investigators are conducting this study to look\n      into the efficacy and safety of IQP-MM-101 in diarrhoea control."
        }, 
        "brief_title": "Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diarrhoea", 
        "condition_browse": {
            "mesh_term": "Diarrhea"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 to 65 years\n\n          -  Good general health\n\n          -  Acute diarrhoea episode defined as at least three watery stools per 24 hours over a\n             period of 48 hours or less\n\n          -  Acute diarrhoea of presumed infectious origin\n\n          -  Patients with usually normal bowel movements (defecations) before onset of diarrhoea,\n             that is, at least three normal stools per week and three or less normal stools per\n             day\n\n          -  Negative pregnancy test (\u00df HCG-test) for women with child bearing potential\n\n          -  Written informed consent is a prerequisite for subject enrollment\n\n        Exclusion Criteria:\n\n          -  Known sensitivity to the ingredients of the device\n\n          -  Fever >38,5\u25e6C\n\n          -  Blood or pus in stools\n\n          -  Dehydration requiring intravenous rehydration\n\n          -  History of chronic diarrhoea (three or more loose or watery stools per day for at\n             least 12 weeks, consecutive or not, in the preceding 12 months)\n\n          -  Use of antidiarrhoeal agents over the month prior to baseline\n\n          -  Diarrhoea possibly induced by antibiotics, laxative agents, thyroid hormones, or\n             colchicine\n\n          -  Irritable bowel syndrome\n\n          -  Any other acute or chronic disease that could interfere with the evaluation of study\n             device\n\n          -  Females who are pregnant or lactating\n\n          -  Subjects who have participated in another clinical trial in the 30 days before\n             treatment period\n\n          -  Inability to comply\n\n          -  Presence of other factor(s) that, in the investigator's judgement, should preclude\n             subject participation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01969214", 
            "org_study_id": "INQ/015213"
        }, 
        "intervention": {
            "arm_group_label": "IQP-MM-101", 
            "description": "Dissolve the effervescent tablets in half a glass of water, to be taken orally\n1 tablet, 3 times a day", 
            "intervention_name": "IQP-MM-101", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10369"
                }, 
                "name": "analyze & realize GmbH"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open Label Study to Assess the Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea", 
        "overall_contact": {
            "email": "falt@analyze-realize.com", 
            "last_name": "Felix Alt", 
            "phone": "+49 30/40 00 81 50"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time (in hours) between the 1st intake of IQP-MM-101 and first formed or hard stool followed by a non watery stool", 
            "safety_issue": "No", 
            "time_frame": "72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01969214"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time (hours) from the first intake to the last watery stool", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Number of stools", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Number of watery stools", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Stool frequency and consistency", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Percentage of patients having recovered within a certain time period (defined as having achieved the primary efficacy endpoint)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Associated symptoms such as nausea, vomiting and abdominal pain", 
                "safety_issue": "Yes", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Time off from work", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Evaluation of energy for \"everyday life\"", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "description": "The subjects and investigators will evaluate independently the safety of the investigational device (global scaled evaluation with \"very good\", \"good\", \"moderate\" and \"poor\").", 
                "measure": "Global evaluation of safety and efficacy by subjects and investigators", 
                "safety_issue": "Yes", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Occurrence of Adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "72 hours"
            }
        ], 
        "source": "InQpharm Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InQpharm Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}